Dr. Shore Discusses Glypican-1 as a Biomarker for Prostate Cancer
Neal D. Shore, MD, FACS, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.
Glypican-1 is a new receptor found to be involved in many different growth processes of malignant cells, says Shore. It is demonstrable in blood, urine, serum, and plasma. He and his colleagues conducted a preliminary pilot study of 300 patients, and they were able to find a cut point, where they could see a very high specificity for demonstrating patients who had cancer versus those who did not.
Traditionally, other biomarkers have had a fairly high sensitivity for true positives or true negatives, but they do not have the specificity at the same time, adds Shore.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
